7-benzyl-1-methyl-3,7-dihydro-purine-2,6-dione | 70404-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7-benzyl-1-methyl-3,7-dihydro-purine-2,6-dione
• 英文别名: 7-Benzyl-1-methyl-3,7-dihydro-purin-2,6-dion；7-benzyl-1-methyl-3,7-dihydro-1H-purine-2,6-dione；1-methyl-7-(phenylmethyl)purine-2,6-dione；7-benzyl-1-methyl-3H-purine-2,6-dione
• CAS: 70404-25-0
• 化学式: C₁₃H₁₂N₄O₂
• 分子量: 256.264
• InChiKey: LEOWVIMYMRWTBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-benzyl-1-methyl-3,7-dihydro-purine-2,6-dione 在 palladium dihydroxide 、 溴 、 sodium acetate 、 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 7-benzyl-8-bromo-3-isobutyl-1-methyl-1H-purine-2,6(3H,7H)-dione
  参考文献：
  名称：

  Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors

  摘要：

  We have discovered potent and selective xanthine PDE5 inhibitors. Compound 25 (PDE5 IC50 = 0.6 nM, PDE6/PDE5 = 101) demonstrated similar functional efficacy and PK profile to Sildenafil (PDE5 IC50 = 3.5 nM, PDE6/PDE5 = 7). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00646-7
• 作为产物：
  描述：

  Ethyl 3-benzyl-5-(methylcarbamoylamino)imidazole-4-carboxylate 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以89%的产率得到7-benzyl-1-methyl-3,7-dihydro-purine-2,6-dione
  参考文献：
  名称：

  1-Substituent Xanthines

  摘要：

  描述了一种方便的一般程序，从易于制备的咪唑前体制备1-烷基、1-芳基和1-氨基黄嘌呤。

  DOI：

  10.1055/s-1995-4017

文献信息

• Substituted xanthines and cytokinin analogues as inhibitors of cytokinin N-glucosylation
  作者：Charles H. Hocart、David S. Letham、Charles W. Parker

  DOI：10.1016/0031-9422(91)85086-f

  日期：1991.1

  raising the amount of free BAP. N -glucosylation of BAP in radish leaves was found to be suppressed most effectively by 1,7-dimethyl-3-(3-methylbutyl)xanthine, 1,7-dimethyl-3-(5-hexenyl)xanthine and 1,7-dimethyl-3-(3-methyl-2-butenyl)xanthine. The first two compounds were also effective inhibitors in radish cotyledons and elevated the concentrations of both free BAP and BAP nucleotide. These results

  摘要 合成了一系列 3-取代黄嘌呤、2-(2-羟基-2-甲基丙基氨基)-9-甲基-6-苄氨基嘌呤和 7-苄氨基恶唑并[5,4-d]嘧啶作为细胞分裂素 N-葡萄糖基化的潜在抑制剂。 . 在玉米叶片段中，发现后一种化合物是测试的最有效抑制剂，可抑制 6-苄氨基嘌呤 (BAP) 的 9-葡糖苷的形成并增加游离 BAP 的量。发现萝卜叶中 BAP 的 N-葡萄糖基化被 1,7-二甲基-3-(3-甲基丁基)黄嘌呤、1,7-二甲基-3-(5-己烯基)黄嘌呤和 1,7-二甲基-3-(3-甲基-2-丁烯基)黄嘌呤。前两种化合物也是萝卜子叶的有效抑制剂，并提高了游离 BAP 和 BAP 核苷酸的浓度。
• Polycyclic guanine derivatives
  申请人：Schering Corporation

  公开号：US05393755A1

  公开（公告）日：1995-02-28

  Novel polycylic guanine derivatives of the formula: ##STR1## wherein J is oxygen or sulfur, R.sup.1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy; R.sup.2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or --(CH.sub.2).sub.m TCOR.sup.20 wherein m is an integer from 1 to 6, T is oxygen or --NH-- and R.sup.20 is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl; R.sup.3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with awl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino; R.sup.a, R.sup.b, R.sup.c, and R.sup.d are defined in the specification; and n is zero or one. The compounds of formulas (I) and (I') are useful as antihypertensive, muscle relaxant and bronchodilating agents.

  新颖的多环鸟嘌呤衍生物的化学式为：##STR1## 其中J为氧或硫，R.sup.1为氢，烷基或烷基取代芳基或羟基；R.sup.2为氢，芳基，杂环芳基，环烷基，烷基或烷基取代芳基，杂环芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基，或--(CH.sub.2).sub.m TCOR.sup.20，其中m为1到6的整数，T为氧或--NH--，R.sup.20为氢，芳基，杂环芳基，烷基或烷基取代芳基或杂环芳基；R.sup.3为氢，卤素，三氟甲基，烷氧基，硫烷基，烷基，环烷基，芳基，氨基磺酰基，氨基，单烷基氨基，二烷基氨基，羟基烷基氨基，氨基烷基氨基，羧基，烷氧羰基或氨基羰基或烷基取代芳基，羟基，烷氧基，氨基，单烷基氨基或二烷基氨基；R.sup.a，R.sup.b，R.sup.c和R.sup.d在规范中有定义；n为零或一。化合物的化学式(I)和(I')可用作降压、肌肉松弛和扩张支气管剂。
• [EN] IMIDAZO [2,1-B] PURINE DERIVATIVES AS TRPA1 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZO[2,1-B]PURINE EN TANT QUE MODULATEURS DE TRPA1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2009144548A1

  公开（公告）日：2009-12-03

  The present invention provides TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1) modulators. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl.

  本发明提供了TRPA（瞬时受体电位亚家族A）调节剂。具体而言，本文描述的化合物可用于治疗或预防由TRPAl（瞬时受体电位亚家族A，成员1）调节剂调节的疾病、症状和/或疾病。此外，本文还提供了制备本文描述的化合物的方法、用于合成的中间体、药物组合物以及用于治疗或预防由TRPAl调节的疾病、症状和/或疾病的方法。
• Traube, Justus Liebigs Annalen der Chemie, 1923, vol. 432, p. 287
  作者：Traube

  DOI：——

  日期：——
• Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity
  作者：Ho-Sam Ahn、Ana Bercovici、George Boykow、Alan Bronnenkant、Samuel Chackalamannil、Jason Chow、Renee Cleven、John Cook、Michael Czarniecki、Carol Domalski、Ahmad Fawzi、Michael Green、Asli Gündes、Ginny Ho、Malvina Laudicina、Neil Lindo、Ke Ma、Mahua Manna、Brian McKittrick、Bita Mirzai、Terry Nechuta、Bernard Neustadt、Chester Puchalski、Kathryn Pula、Lisa Silverman、Elizabeth Smith、Andrew Stamford、Richard P. Tedesco、Hsingan Tsai、Deen Tulshian、Henry Vaccaro、Robert W. Watkins、Xiaoyu Weng、Joseph T. Witkowski、Yan Xia、Hongtao Zhang

  DOI：10.1021/jm9608467

  日期：1997.7.1

  Tetracyclic guanines have been shown to be potent and selective inhibitors of the cGMP-hydrolyzing enzymes PDE1 and PDE5. In general, these compounds are inactive or only weakly active as inhibitors of PDE3, which is a major isozyme involved in cAMP hydrolysis. Structure-activity relationships are developed at N-1, C-2, N-3, and N-5 on the core nucleus. Compound 31, with an IC50 of 70 pM, is the most potent inhibitor of PDE1, while 50, with an IC50 of 4 nM, is the most potent inhibitor of PDE5. Compounds 20, 22, 30, and 50 are potent dual inhibitors with IC50 values below 30 nM for both PDE1 and PDE5. Compounds 12, 20, and 28 reduced blood pressure by more than 45 mmHg when administered orally at 10 mg/kg to the spontaneously hypertensive rat (SHR).